Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia Therapeutics and its phase 1-stage myeloma therapy. Kelonia is a lentiviral vector delivery specialist whose lead program is a BCMA-targeting in vivo CAR-T called KLN-1010.

Eli Lilly (NYSE: LLY) is reportedly in talks to acquire cancer biotech Kelonia Therapeutics in a deal that could be worth more than $7 billion (1). The proposed acquisition would give Lilly access to Kelonia's experimental gene delivery platform,

Eli Lilly announced Monday that it is acquiring Kelonia Therapeutics, a developer of gene therapies with a particular focus on cancer treatment, in a deal valued at up to $7 billion in cash.

Eli Lilly is rumoured to be planning to spend some more of the cash raked in from its fast-growing incretin therapies for obesity and diabetes on another acquisition, this time for cell therapy developer Kelonia Therapeutics. The Wall Street Journal has ...